Effect of Stellate Ganglion Block Combined With Facial Nerve Block on the Treatment of Idiopathic Facial Paralysis

Not Applicable

Completed

• Conditions: Peripheral Facial Palsy
• Interventions: Procedure: Facial Nerve Block; Procedure: Stellate Ganglion Block; Drug: Mecobalamin Tablets

• Registration Number: NCT04800666
• Lead Sponsor: Zhuan Zhang

Brief Summary

Peripheral facial palsy is caused by damage to the facial nerve at any site of the peripheral branches after the facial nucleus.Stellate ganglion block is performed to treat peripheral facial palsy because it increases blood flow and promotes nerve regeneration.Facial Nerve Block worked with elimination of local inflammation of nerve and oppression. Facial nerve block is a treatment that inject drugs into the damaged nerve around to eliminate local inflammation and compression of the nerve.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-03-01
• Study First Submitted: 2021-03-11
• Study First Submitted QC: 2021-03-13
• Study First Posted: 2021-03-16
• Primary Completion: 2022-03-30
• Study Completion: 2022-03-30
• Status Verified: 2022-11
• Last Update Submitted: 2022-11-20
• Last Update Posted: 2022-11-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Diagnosed by clinical and neurological assessment as one-sided simple facial

• Age 18 to 75 years
• HBGS above Ⅳ
• the course of IFP not over 7 days.

Exclusion Criteria

• Coagulation dysfunction
• plate plate plate shape, quantity or abnormal function
• mental system diseases
• Gillan-Bahrain syndrome
• cancer, mumps, shingles infection, jaw facial pus lymph nodeitis, encephalitis, -cerebral hemorrhage and other diseases
• local infection or systemic infectious disease at the puncture site
• can not accept to nerve block

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Facial Nerve Block Group	Facial Nerve Block	Facial Nerve Block and oral Mecobalamin Tablets
Facial Nerve Block Group	Mecobalamin Tablets	Facial Nerve Block and oral Mecobalamin Tablets
Stellate Ganglion Block Group	Stellate Ganglion Block	Facial Nerve Block and Stellate Ganglion Block and oral Mecobalamin Tablets
Stellate Ganglion Block Group	Facial Nerve Block	Facial Nerve Block and Stellate Ganglion Block and oral Mecobalamin Tablets
Stellate Ganglion Block Group	Mecobalamin Tablets	Facial Nerve Block and Stellate Ganglion Block and oral Mecobalamin Tablets
D Group	Facial Nerve Block	Facial Nerve Block
C Group	Mecobalamin Tablets	control

Primary Outcome Measures

Name	Time	Method
Change from Baseline House-Brackmann	Baseline ,change from baseline House-Brackmann at 3 days,6 days,9 days,14 days,one month,two month	The House-Brackmann scale is a nerve grading system developed in 1985 by Los Angeles otolaryngologists Dr. John W. House and Dr. Derald E. Brackmann. It is used to characterize the severity of a facial paralysis patient's symptoms.
Change from Baseline Sunnybrook	Baseline,change from baseline Sunnybrook at 3 days,6 days,9 days,14 days, one month,two month	Sunnybrook is a new facial nerve function of subjective assessment system.It is based on both static and dynamic aspects.

Trial Locations

Locations (1)

the Affiliated Hospital of Yangzhou University; 🇨🇳 Yangzhou, Jiangsu, China